Perspectives on TLR2 agonist use in the road map to HBV cure.

Pieterman RFA, Durantel D, Janssen HLA, Sprengers D, Buschow SI

DOI: 10.1016/j.antiviral.2026.106447
Published: 2026 Aug
Container: Antiviral research
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.antiviral.2026.106447,
  title = {Perspectives on TLR2 agonist use in the road map to HBV cure.},
  author = {Pieterman RFA and Durantel D and Janssen HLA and Sprengers D and Buschow SI},
  year = {2026},
  journal = {Antiviral research},
  doi = {10.1016/j.antiviral.2026.106447},
  url = {https://doi.org/10.1016/j.antiviral.2026.106447}
}

RIS

TY  - JOUR
TI  - Perspectives on TLR2 agonist use in the road map to HBV cure.
AU  - Pieterman RFA
AU  - Durantel D
AU  - Janssen HLA
AU  - Sprengers D
AU  - Buschow SI
PY  - 2026
JO  - Antiviral research
DO  - 10.1016/j.antiviral.2026.106447
UR  - https://doi.org/10.1016/j.antiviral.2026.106447
ER  -

APA

RFA, P., D, D., HLA, J., D, S., & SI, B. (2026). Perspectives on TLR2 agonist use in the road map to HBV cure.. Antiviral research. https://doi.org/10.1016/j.antiviral.2026.106447

Source records

pubmed · retrieved 2026-09-26T07:24:18.529Z
europe-pmc · retrieved 2026-09-26T07:24:18.541Z